Literature DB >> 15302210

Overexpression of adenovirus E3-11.6K protein induces cell killing by both caspase-dependent and caspase-independent mechanisms.

Aihua Zou1, Isabella Atencio, Whei-Mei Huang, Mark Horn, Murali Ramachandra.   

Abstract

Recent studies have shown enhanced antitumor efficacy with adenoviruses that either lack E1B-19K or overexpress E3-11.6K (also known as adenoviral death protein). E1B-19K is a well-characterized anti-apoptotic protein, and viruses with E1B-19K deletions show increased cytopathicity. However, the mechanism of cell killing by E3-11.6K, which plays an important role in killing infected cells and virion release, is not well characterized. To understand the mechanism of cell killing following E3-11.6K overexpression, we constructed a recombinant adenovirus, Ad-ME, by introducing viral major late promoter upstream of the E3-11.6K sequence. Similar to the E1B-19K-deleted virus, E1B/19K-, Ad-ME induced cell death to a greater extent than the wild-type virus. Cell shrinkage, membrane blebbing, activation of caspases 3 and 9, cleavage of poly(ADP-ribose)polymerase (PARP), DNA degradation, and ratio of ADP to ATP in Ad-ME-infected cells indicated that apoptosis contributes to cell death following E3-11.6K overexpression. However, the levels of activation of caspases 3 and 9 were lower in cells infected with Ad-ME compared to those infected with E1B/19K-. Furthermore, cell killing by Ad-ME was not effectively inhibited by Z-VAD-FMK, a general caspase inhibitor. Taken together, our results suggest both caspase-dependent and caspase-independent mechanisms of cell killing due to overexpression of E3-11.6K.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15302210     DOI: 10.1016/j.virol.2004.06.007

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  15 in total

1.  Genetic identification of adenovirus type 5 genes that influence viral spread.

Authors:  T Subramanian; S Vijayalingam; G Chinnadurai
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

2.  Identification of integrin alpha3 as a new substrate of the adenovirus E4orf6/E1B 55-kilodalton E3 ubiquitin ligase complex.

Authors:  Frédéric Dallaire; Paola Blanchette; Peter Groitl; Thomas Dobner; Philip E Branton
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

Review 3.  Oncolytic virus as a cancer stem cell killer: progress and challenges.

Authors:  Jingzhen Ding
Journal:  Stem Cell Investig       Date:  2014-12-28

4.  Viral Vector Biosafety in Laboratory Animal Research.

Authors:  Dalis E Collins; Jon D Reuter; Howard G Rush; Jason S Villano
Journal:  Comp Med       Date:  2017-06-01       Impact factor: 0.982

5.  Adeno-associated virus induces apoptosis during coinfection with adenovirus.

Authors:  Jennifer M Timpe; Kristin C Verrill; Bret N Black; Han-Fei Ding; James P Trempe
Journal:  Virology       Date:  2006-09-29       Impact factor: 3.616

6.  Modulation of apoptosis and immune signaling pathways by the Hantaan virus nucleocapsid protein.

Authors:  Steven J Ontiveros; Qianjun Li; Colleen B Jonsson
Journal:  Virology       Date:  2010-03-12       Impact factor: 3.616

7.  Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles.

Authors:  Han Hsi Wong; Nicholas R Lemoine; Yaohe Wang
Journal:  Viruses       Date:  2010-01       Impact factor: 5.818

8.  Adenovirus death protein (ADP) is required for lytic infection of human lymphocytes.

Authors:  V K Murali; D A Ornelles; L R Gooding; H T Wilms; W Huang; A E Tollefson; W S M Wold; C Garnett-Benson
Journal:  J Virol       Date:  2013-11-06       Impact factor: 5.103

Review 9.  Conditionally replicating adenoviruses for cancer treatment.

Authors:  Youssef Jounaidi; Joshua C Doloff; David J Waxman
Journal:  Curr Cancer Drug Targets       Date:  2007-05       Impact factor: 3.428

10.  HtrA2/Omi terminates cytomegalovirus infection and is controlled by the viral mitochondrial inhibitor of apoptosis (vMIA).

Authors:  A Louise McCormick; Linda Roback; Edward S Mocarski
Journal:  PLoS Pathog       Date:  2008-05-09       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.